R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family clinical, genetic, and neuropathological study

JAMA Neurology

Volumn 72, Issue 8, 2015, Pages 920-927

  Korvatska, Olena ^a   Leverenz, James B ^b   Jayadev, Suman ^c   McMillan, Pamela ^a,d   Kurtz, Irina ^a   Guo, Xindi ^a   Rumbaugh, Malia ^c   Matsushita, Mark ^e   Girirajan, Santhosh ^f   Dorschner, Michael O ^a,e   Kiianitsa, Kostantin ^e   Yu, Chang En ^a,g   Brkanac, Zoran ^a   Garden, Gwenn A ^c,e   Raskind, Wendy H ^a,d,e   Bird, Thomas D ^c,e,g  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^d Education and Clinical Center   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f PENNSYLVANIA STATE UNIVERSITY   (United States)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM BINDING PROTEIN; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; APOE4 GENE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EXOME; FAMILIAL DISEASE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MISSENSE MUTATION; MORPHOMETRICS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TREM2 GENE; UNC5C GENE; VERY ELDERLY; BRAIN; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; ONSET AGE; PATHOLOGY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC;

EID: 84938912653     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0979     Document Type: Article

References (38)

1. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65(3): 664-670.
2. Bird TD. Genetic factors in Alzheimer's disease. N Engl J Med. 2005;352(9):862-864.
3. Green RC, Cupples LA, Go R, et al; MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329-336.
4. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004;6(4): 192-196.
5. Gatz M, Mortimer JA, Fratiglioni L, et al. Potentially modifiable risk factors for dementia in identical twins. Alzheimers Dement. 2006;2(2):110-117.
6. Jonsson T, Stefansson H, Ph DS, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2):107-116.
7. Guerreiro R, Wojtas A, Bras J, et al; Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-127.
8. Hooli BV, Parrado AR, Mullin K, et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology. 2014;83(15): 1353-1358.
9. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751-755.
10. Korvatska O, Strand NS, Berndt JD, et al. Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet. 2013;22(16):3259-3268.
11. Girirajan S, Dennis MY, Baker C, et al. Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder. Am J Hum Genet. 2013;92(2): 221-237.
12. Cooper GM, Coe BP, Girirajan S, et al. A copy number variation morbidity map of developmental delay. Nat Genet. 2011;43(9):838-846.
13. Karch CM, Cruchaga C, Goate AM. Alzheimer's disease genetics: from the bench to the clinic. Neuron. 2014;83(1):11-26.
14. Wetzel-Smith MK, Hunkapiller J, Bhangale TR, et al; Alzheimer's Disease Genetics Consortium. A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nat Med. 2014;20(12):1452-1457.
15. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
16. Mann DM. A commentary on the diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging. 1997;18(4) (suppl):S51-S52.
17. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-486.
18. Cuyvers E, Bettens K, Philtjens S, et al; BELNEU Consortium. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2014;35(3):726.e11-29.
19. Slattery CF, Beck JA, Harper L, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10(6):602-608.e4.
20. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013;8:19.
21. Cady J, Koval ED, Benitez BA, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71 (4):449-453.
22. Kleinberger G, Yamanishi Y, Suárez-Calvet M, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243): 243ra86.
23. Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160(6):1061-1071.
24. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71(3): 656-662.
25. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70(1):78-84.
26. Le Ber I, De Septenville A, Guerreiro R, et al. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol Aging. 2014;35(10):2419.e23-5.
27. Benitez BA, Cooper B, Pastor P, et al. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging. 2013;34(6): 1711.e15-7.
28. Pottier C, Wallon D, Rousseau S, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis. 2013;35(1): 45-49.
29. Zhao YY, Yan DJ, Chen ZW. Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. 2013;284(1-2):75-83.
30. Chinnasamy P, Lutz SE, Riascos-Bernal DF, et al. Loss of Allograft inflammatory factor-1 ameliorates experimental autoimmune encephalomyelitis by limiting encephalitogenic CD4 T cell expansion [published online January 6, 2015]. Mol Med. doi:10.2119/molmed.2014.00264.
31. Gan L, Ye S, Chu A, et al. Identification of cathepsin B as a mediator of neuronal death induced by Abeta-activated microglial cells using a functional genomics approach. J Biol Chem. 2004;279(7):5565-5572.
32. Serrano-Pozo A, Gómez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol. 2013;182(6):2332-2344.
33. Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015;212(3):287-295.
34. Kanazawa H, Ohsawa K, Sasaki Y, Kohsaka S, Imai Y. Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma-dependent pathway. J Biol Chem. 2002;277(22):20026-20032.
35. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol. 2015;16(3):229-236.
36. Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8(4): e60921.
37. Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain. 2013;136(pt 9):2677-2696.
38. Otero K, Turnbull IR, Poliani PL, et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol. 2009;10(7):734-743.